FIGURE 1.

DZNep controls donor CD8⁺ T-cell–mediated GVHD. Lethally irradiated B6 recipients (1000 rads) were transplanted intravenously with TCD-BM (6.0×10⁶) derived from C3H mice or with TCD-BM+CD44^lowCD8⁺ T cells (1.0×10⁶). Eight doses of DZNep (1 mg/kg; D3, D5, D7, D9, D11, D13, D15, and D17) were injected subcutaneously to recipients (DZNep; n=12; ▲) with PBS treatment as positive control (PBS; n=12; ◊) and TCD-BM transplanted mice as negative control (TCD-BM; n=8; •). Survival data (A), body weight loss (B), and clinical score (C) were monitored over time. Tissues were collected on day 14 (before DZNep treatment) after allo-HSCT for histologic GVHD examination (×100) (D).